Analyzing clinical results of dexamethasone implant effect on macular thickness

Publication
Video
Modern Retina Digital EditionModern Retina Summer 2021
Volume 1
Issue 1
Conference|ARVO

Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

Daniel F. Kiernan, MD, a vitreoretinal surgeon at The Eye Associates, Sarasota, Florida, discusses the highlights of his 2021 ARVO virtual presentation on the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on optical coherence tomography (OCT) testing following vitreoretinal surgery.

See more ARVO coverage

Articles in this issue
Sustained-release anti-inflammatory therapy is valuable in noninfectious uveitis
Sustained-release anti-inflammatory therapy is valuable in noninfectious uveitis
Pediatric ophthalmologists target inherited retinal diseases
Pediatric ophthalmologists target inherited retinal diseases
Gaining a greater understanding of AMD
Gaining a greater understanding of AMD
VEGF and beyond: therapeutic targeting in retinal vascular disorders
VEGF and beyond: therapeutic targeting in retinal vascular disorders
Laser imaging system may offer early detection, treatment for eye diseases that cause blindness
Laser imaging system may offer early detection, treatment for eye diseases that cause blindness
Analyzing clinical results of dexamethasone implant effect on macular thickness
Analyzing clinical results of dexamethasone implant effect on macular thickness

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!
Recent Videos
Carl Danzig, MD, director of vitreo-retinal services at the Rand Eye Institute in Deerfield Beach, Florida, shared an update on his research in OCS-01 drops for diabetic macular edema during ARVO
Jennifer Lim, MD, FARVO, FASRS, from the University of Illinois at Chicago, discussed her ARVO presentation on sickle cell retinopathy. She highlighted improvements in retinal surgery techniques and instrumentation.
At ARVO 2025, Christine Kay, MD, shares interim results from the PRISM trial population extension cohort
ARVO 2025: Rishi Singh, MD, discusses real-world clinical outcomes in patients with DME
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Abby Markward and Hattie Hayes discuss the ASCRS Annual Meeting, the ASOA Annual Meeting, and the Retina Day event.
Related Content
Positive preclinical data on melanocortin agonists for retinopathy

Positive preclinical data on melanocortin agonists for retinopathy

Kassi Filkins
May 14th 2025
Article
Integrating AI to manage DR in a primary care setting

Integrating AI to manage DR in a primary care setting

Alex Delaney-Gesing ;David Hutton
December 1st 2020
Podcast
AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies

Hattie Hayes
May 13th 2025
Article
What to expect from virtual AAO 2020

What to expect from virtual AAO 2020

Alex Delaney-Gesing
November 5th 2020
Podcast
Patient comfort and using chlorhexidine for anti-sepsis

Patient comfort and using chlorhexidine for anti-sepsis

Sydney M Crago
May 12th 2025
Article
Boehringer Ingelheim launches two Phase 2 clinical trials for its geographic atrophy treatment candidates

Boehringer Ingelheim launches two Phase 2 clinical trials for its geographic atrophy treatment candidates

Emily Kaiser Maharjan
May 12th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.